# Neoadjuvant therapy with cadonilimab in a patient with MSI-H/dMMR colorectal cancer: a case report

## TL;DR

A 37-year-old woman with a specific type of colorectal cancer showed a complete response to a new immunotherapy drug before surgery.

## Contribution

This case report demonstrates the effectiveness and safety of cadonilimab in neoadjuvant treatment for dMMR/MSI-H colorectal cancer.

## Key findings

- The patient achieved significant tumor regression after nine cycles of cadonilimab.
- A pathological complete response was observed after surgery.
- The treatment had a favorable safety profile.

## Abstract

Neoadjuvant immunotherapy for mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer continues to accumulate compelling clinical evidence. This report presents the case of a 37-year-old female who presented with moderate anemia (hemoglobin: 69 g/L) and was subsequently diagnosed with dMMR/MSI-H descending colon cancer. Following nine cycles of cadonilimab, a novel PD-1/CTLA-4 bispecific antibody, the patient achieved significant tumor regression and subsequent pathological complete response (pCR) after surgery, with a favorable safety profile observed throughout the treatment course. This case provides valuable clinical evidence supporting the efficacy and safety of cadonilimab in the neoadjuvant setting for dMMR/MSI-H colorectal cancer.